# US 2023/0069100 A1 · N-(3-amino-3-oxopropyl)-2-[(1-methyl-4-nitro-1h-imidazol-5-yl)thio]benzamide and its use for treating hiv infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0069100 A1
- Document ID: US20230069100A1
- Status: Published application
- Kind: A1
- Application number: 17/785,155
- Filed: 2020-12-17
- Published: 2023-03-02
- Earliest claimed: 2019-12-17
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services
- Inventors: Daniel H. Appella; Herman Nikolayevskiy; Marco Robello; Michael T. Scerba
- Web page: https://patentgrep.com/patent/US20230069100A1

## CPC

- A61K 31/4164: 1,3-Diazoles
- A61K 31/4174: Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/52: Purines, e.g. adenine
- A61K 31/5365: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/18: for HIV
- C07D 233/92: attached in position 4 or 5
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed is a compound of formula (I): for treating or preventing a human immunodeficiency virus (HIV) infection in a mammal, for inhibiting or preventing maturation of an immature human immunodeficiency virus (HIV) to a mature HIV, and for preventing or inhibiting a human immunodeficiency virus (HIV) infection in a mammal having at least one HIV viral particle on a surface thereof.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A compound of formula (I):
or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 20)

A pharmaceutical composition comprising the compound of claim 20, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 22 (depends on 20)

A method of treating or preventing a human immunodeficiency virus (HIV) infection in a mammal in need thereof comprising administering to the mammal an effective amount of a compound of claim 20 or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the HIV comprises a virus selected from the group consisting of HIV Clade A, HIV Clade B, HIV Clade C, HIV Clade D, HIV Clade E, HIV Clade F, HIV Clade G, and HIV Clade O.

### Claim 24 (depends on 22)

The method according to claim 22, wherein the compound or salt is administered orally.

### Claim 25 (depends on 22)

The method according to claim 22, further comprising administering to the mammal one, two, three, or four additional therapeutic agents.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the one, two, three, or four additional therapeutic agents are selected from the group consisting of combination drugs for HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, latency reversing agents, compounds that target the HIV capsid, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins, HIV p17 matrix protein inhibitors, IL-13 antagonists, peptidyl-prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitor, HIV vif gene modulators, Vif dimerization antagonists, HIV-1 viral infectivity factor inhibitors, TAT protein inhibitors, HIV-1 Nef modulators, Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, Rev protein inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain containing protein 1 modulators, HIV ribonuclease H inhibitors, retrocyclin modulators, CDK-9 inhibitors, dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, Complement Factor H modulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin dependent kinase inhibitors, proprotein convertase PC9 stimulators, ATP dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH-oxidase inhibitors, pharmacokinetic enhancers, HIV gene therapy, HIV gene editing, and HIV vaccines, and any combination thereof.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the one, two, three, or four additional therapeutic agents are selected from the group consisting of entry inhibitors, HIV non-nucleoside reverse transcriptase inhibitors, HIV non-nucleotide reverse transcriptase inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV nucleotide reverse transcriptase inhibitors, integrase inhibitors, protease inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, and pharmacokinetic enhancers, and any combination thereof.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the additional therapeutic agents comprise a combination of antiretroviral agents selected from the group consisting of:
tenofovir, emtricitabine, and raltegravir;
tenofovir, emtricitabine, and dolutegravir;
abacavir, lamivudine, and dolutegravir;
tenofovir, emtricitabine, and elvitegravir; and
tenofovir, emtricitabine, ritonavir, and darunavir.

### Claim 29 (depends on 22)

The method according to claim 22, which inhibits or prevents maturation of an immature human immunodeficiency virus (HIV) to a mature HIV.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the HIV comprises a virus selected from the group consisting of HIV Clade A, HIV Clade B, HIV Clade C, HIV Clade D, HIV Clade E, HIV Clade F, HIV Clade G, and HIV Clade O.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the compound or salt thereof is administered orally.

### Claim 32 (depends on 28)

The method according to claim 28, further comprising administering to the mammal one, two, three, or four additional therapeutic agents.

### Claim 33 (depends on 32)

The method according to claim 32, wherein the one, two, three, or four additional therapeutic agents are selected from the group consisting of combination drugs for HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, latency reversing agents, compounds that target the HIV capsid, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins, HIV p17 matrix protein inhibitors, IL-13 antagonists, peptidyl-prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitor, HIV vif gene modulators, Vif dimerization antagonists, HIV-1 viral infectivity factor inhibitors, TAT protein inhibitors, HIV-1 Nef modulators, Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, Rev protein inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain containing protein 1 modulators, HIV ribonuclease H inhibitors, retrocyclin modulators, CDK-9 inhibitors, dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, Complement Factor H modulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin dependent kinase inhibitors, proprotein convertase PC9 stimulators, ATP dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH-oxidase inhibitors, pharmacokinetic enhancers, HIV gene therapy, HIV gene editing, and HIV vaccines, and any combination thereof.

### Claim 34 (depends on 32)

The method according to claim 32, wherein the one, two, three, or four additional therapeutic agents are selected from the group consisting of entry inhibitors, HIV non-nucleoside reverse transcriptase inhibitors, HIV non-nucleotide reverse transcriptase inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV nucleotide reverse transcriptase inhibitors, integrase inhibitors, protease inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, and pharmacokinetic enhancers, and any combination thereof.

### Claim 35 (depends on 32)

The method according to claim 32, wherein the additional therapeutic agents comprise a combination of antiretroviral agents is selected from the group consisting of:
tenofovir, emtricitabine, and raltegravir;
tenofovir, emtricitabine, and dolutegravir;
abacavir, lamivudine, and dolutegravir;
tenofovir, emtricitabine, and elvitegravir; and
tenofovir, emtricitabine, ritonavir, and darunavir.

### Claim 36 (depends on 22)

The method according to claim 22, which prevents or inhibits a human immunodeficiency virus (HIV) infection in a mammal in need thereof, wherein the mammal has at least one HIV viral particle on a surface thereof.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the HIV comprises a virus selected from the group consisting of HIV Clade A, HIV Clade B, HIV Clade C, HIV Clade D, HIV Clade E, HIV Clade F, HIV Clade G, and HIV Clade O.

### Claim 38 (depends on 36)

The method according to claim 36, which comprises topically administering the compound or a pharmaceutically acceptable salt thereof to the surface in the form of a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

### Claim 39 (depends on 37)

The method according to claim 37, which comprises topically administering the compound or a pharmaceutically acceptable salt thereof to the surface in the form of a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
